Researchers say that low-dose naltrexone proved an effective therapy against Crohn's disease. According to the study, 89 percent of treated patients experienced significant improvement in their symptoms, and two-thirds experienced remission.
"This is a novel, yet effective, approach to treating a common disease," says Jill Smith, Professor of Gastroenterology at Hershey Medical Center. A follow-up controlled trial, sponsored by the Broad Medical Foundation and the National Institutes of Health, has been launched to confirm the results of the first study. "We have already been approached by biotech companies with an interest in licensing this therapy," she says. "Because naltrexone is already approved for other uses, it should be a relatively inexpensive process to obtain FDA approval for its use in Crohn's disease."
- check out the release for more information